Skip to content
MARKETS / NYSE / ITGR
NYSE · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · LARGE CAP

Integer Holdings Corp. ITGR

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.9B
▲ 8.0% YoY
$102.8M
▼ 14.3% YoY
$105.1M
▲ 5.3% YoY
In brief

What this company does

Integer Holdings Corporation, headquartered in Plano, Texas, is a medical device contract development and manufacturing organization serving the Cardio and Vascular, Neuromodulation, and Cardiac Rhythm Management markets. It operates its business in one reportable segment and derives its revenue from three principal product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. In 2025, approximately 53% of the company's products sold were shipped to locations in the United States. During 2025, three of its customers, Abbott Laboratories, Boston Scientific and Medtronic, were each in excess of 10% of total sales and collectively accounted for 49% of total sales. As of December 31, 2025, Integer employed approximately 11,000 associates, in addition to a contingent workforce of approximately 400. As of December 31, 2025, its workforce was distributed 43% in the United States, 25% in Mexico and 15% in Ireland.

Written from the business description in Integer Holdings Corporation's annual report to the U.S. Securities and Exchange Commission, filed 23 February 2026. Every sentence was checked against that document before publication.

Growth
USD 1.9B
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.9 · Net income 0.1
0.8B1.6B200920112013201520172019202120232025
Compound annual growth
+11.7%
+11.5%
+8.8%
+8.7%
+15.7%
+5.9%
+7.8%
+13.2%
+4.4%
+5.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +11.5% a year over five years — but profit grew slower: net income at +5.9%, earnings per share at +4.4%.

The share count rose from 0.03B to 0.03B over the period.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
6 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 11.9% · Net 5.5%
5.0%10.0%-0.5%-1.0%-1.5%200920112013201520172019202120232025
ROE
FY2025 · ROE 6.1%
5%10%15%-1%-2%200920112013201520172019202120232025

Each USD of equity produced 6 cents of profit this year.

Cash & shareholders
USD 46.4M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 105.1
50M100M-20M200920112013201520172019202120232025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 46.4
20M40M202320242025

USD 46.4M in buybacks — 45% of the year's profit went back to shareholders.

Total assetsUSD 3.4B
EquityUSD 1.7B
CashUSD 17.2M
Gross debtUSD 1.2B
Net debtUSD 1.2B
Current ratio3.32×

Net debt stands at 67% of equity.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B1.91.71.61.31.21.11.31.21.11.10.80.70.70.60.60.50.5
Operating income $B0.20.20.20.10.10.10.20.20.10.10.00.10.10.00.10.10.0
EBITDA $B0.40.30.30.20.20.20.20.20.20.20.10.10.10.10.10.10.0
Income tax $B0.00.00.00.00.00.00.00.0−0.00.0−0.00.00.00.00.00.0−0.0
Net income $B0.10.10.10.10.10.10.10.20.10.0−0.00.10.0−0.00.00.0−0.0
Free cash flow $B0.10.10.10.00.10.10.10.10.10.0−0.00.10.00.00.10.10.1
EPS, diluted $2.893.362.691.992.912.332.925.152.080.19−0.292.141.43−0.201.401.40−0.39
Dividend / sh $·················
Payout %·················
ROE %6.17.66.24.87.46.48.717.28.20.8−1.09.67.1−1.07.48.2−2.4
Shares out B0.030.030.030.030.030.030.030.030.030.030.030.030.020.020.020.02·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 83 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 12 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image